Quantcast

Latest Novartis Group Stories

2014-06-17 08:29:10

Submission follows receipt of Breakthrough Therapy designation in April 2014, highlighting unmet need for a licensed vaccine for serogroup B in the US(1) BASEL, Switzerland, June 17, 2014 /PRNewswire/ -- Novartis announced today the submission of a Biologic License Application (BLA) to the US Food and Drug Administration (FDA) for marketing approval for the use of Bexsero(®) (Multicomponent Meningococcal Group B Vaccine [recombinant, adsorbed]) to help protect against invasive meningococcal...

2014-06-16 08:28:43

Cell-culture technology is a modern alternative to manufacture influenza vaccines without chicken eggs, with potential to rapidly respond to a pandemic[1] BASEL, Switzerland, June 16, 2014 /PRNewswire/ -- Novartis today announced that the US Food and Drug Administration (FDA) licensed its manufacturing facility in Holly Springs, N.C. for the production of cell-culture influenza vaccines. This is the first US facility of its kind and is now approved for commercial production. The site will...

2014-02-26 08:28:23

DORVAL QC, Feb. 26, 2014 /CNW/ - Novartis announced today that Bexsero(®) (Multicomponent Meningococcal B Vaccine [recombinant, adsorbed]) is now available to doctors and pharmacists across Canada. The vaccine is approved for use in individuals from two months through 17 years of age in Canada. Infants, toddlers and adolescents are at the greatest risk of meningococcal serogroup B (MenB) infection.(1) Bexsero(®) is the first broad-coverage vaccine to help protect against MenB...

2014-02-24 08:28:29

- FDA granted special use of Bexsero for nearly 20,000 UCSB students and staff in response to outbreak; the vaccine is licensed in Europe, Australia and Canada CAMBRIDGE, Mass., Feb. 24, 2014 /PRNewswire/ -- Novartis announced today that its meningococcal serogroup B (MenB) vaccine, Bexsero(®) (Meningococcal Group B Vaccine [rDNA, component, adsorbed]), will be used as part of a vaccination program at the University of California Santa Barbara (UCSB) that began today and will end on March 7....

2014-01-13 16:25:12

-- Ultibro(TM) Breezhaler®1(QVA149), a long-term once-daily dual bronchodilator, received Health Canada approval on December 23rd 2013 for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema -- Pivotal Phase III IGNITE data showed QVA149 significantly improved lung function and patient-reported outcomes including...

2013-11-07 23:04:16

Reportbuyer.com just published a new market research report: Femtosecond Lasers for Cataract Surgery Market. London (PRWEB) November 07, 2013 WinterGreen Research announces that it has published a new study Femtosecond Lasers for Cataract Surgery Market Shares, Strategy, and Forecasts, Worldwide, 2013 to 2019. The 2013 study has 301 pages, 78 tables and figures. Worldwide markets are poised to achieve continuing growth as the aging population worldwide develops cataracts and need surgery....


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related